Cellectricon, a collaborative services provider dedicated to advance drug discovery and research in the areas of chronic pain and CNS disease, has appointed Professor Henrik Zetterberg to its scientific advisory board. Professor Zetterberg brings extensive expertise in Alzheimer’s disease and other neurodegenerative brain disorders.Read more
Thursday May 3 @ 3 pm CEST (9 am EDT)
Join our webinar to:
Camilla Svensson, Associate Professor and research group leader for Molecular Pain research at the Department of Physiology and Pharmacology, Karolinska Institutet.
To further enhance Cellectricon’s expertise in Chronic Pain drug discovery, the company is today announcing the addition of another highly respected specialist, Professor Camilla Svensson, to its scientific advisory board.Read more
Cellectricon has signed a license agreement with Fluicell AB, granting the exclusive right, inter alia, to sell the Dynaflow Resolve technology worldwide and to use the related IP rights.
The Dynaflow Resolve system is considered by many, to be the premier secondary ion channel screening platform on the market, offering high time resolution for any cell type, any ion channel, and in any patch clamp configuration. Launched in 2004, the Dynaflow platform is an established product with a global user base within big pharma and biotech companies. The Dynaflow platform is complementary to Fluicell´s BioPen system for single-cell-based discovery using optical readouts such as fluorescence microscopy. Both are state-of-the art microfluidic-based technologies which appeal to discerning medical, biology and pharma professionals worldwide, that wish to get the most out of their experiments.Read more
Cellectricon continues to grow and we are now looking to fill two positions; an assay development and screening scientist and a laboratory assistant.
The employments offers exciting opportunities to provide important support to our ongoing customer projects. Learn more about Cellectricon and the two positions on our Careers page.Read more